Company
Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

LogicBio Therapeutics

Main focus: Genomic medicines for genetic diseases

Company stage: Clinical

Diseases (gene editing): methylmalonic acidemia (MMA), Crigler-Najjar syndrome, tyrosinemia type 1, Wilson disease, others undisclosed

Genome editing tool: GeneRide

Funding stage: Public (NASDAQ:LOGC)

Location: Lexington, MA, USA

Website: https://www.logicbio.com/

Pipeline: https://www.logicbio.com/pipeline

Partners: Takeda Pharmaceuticals, Daiichi Sankyo, CANbridge Pharmaceuticals

LogicBio Therapeutics develops its GeneRide™ platform as a novel approch to gene editing. The technology harnesses the cells' natural DNA repair processes and does not require an externally supplied nuclease. The company currenly has one clinical development programme, targeting the rare disease methylmalonic acidemia. This candiate is currently being tested in a Phase I/II clinical trial.

Company: LogicBio Therapeutics
close
Search CRISPR Medicine